Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 15/20 | 0.60 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218810 | 0.81 | KMT2A (0.59) | RPA1PPP1CAALDH1A1SMN1; SMN2 | |
| SCHEMBL3975817 | 0.81 | ALDH1A1 (0.72) | RPA1PPP1CAALDH1A1SMN1; SMN2 | |
| SCHEMBL4012242 | 0.80 | CSF1R (0.48) | RPA1SMN1; SMN2 | |
| SCHEMBL17064405 | 0.74 | KLKB1 (0.52) | RPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1514551 | 0.73 | RPA1 (0.76) | RPA1PPP1CA | |
| SCHEMBL15529154 | 0.72 | ALDH1A1 (0.43) | RPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30882662 | 0.71 | CNR1 (0.52) | PPP1CAALDH1A1 | |
| SCHEMBL2294536 | 0.71 | MAPT (0.66) | RPA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18358805 | 0.71 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL18358776 | 0.71 | ALDH1A1 (0.61) | RPA1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | RPA1 3051/4885PPP1CA 2245/4885TTR 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.